Similarly, a study by Hu et al. examined 834 esophageal cancer patients and another by Guo et al. (2019) assessed 82 metastatic prostate cancer patients, both demonstrating that patients with a low HALP score had a worse prognosis [34,74]. Here, NAT10 is linked to metastatic prostate carcinoma.